|
| |
| Cat. No |
Model |
Description |
Unit |
Price
(VAT별도) |
납기 |
재고 |
DataSheet |
주문/견적 |
| LCA-24-367007 |
AP14451PU-N |
ABL1//Human/Rabbit |
1/EA |
|
|
|
 |
문의 |
|
|
|
|
|
|
|
Subject
|
ABL1 |
|
Description
|
/ Human/Rabbit |
|
Clonality
|
Mono |
|
Company
|
Acris Antibodies GmbH |
|
Application
|
Enzyme Immunoassay, Western blot / Immunoblot |
|
Conjugation
|
|
|
Immunogen
|
|
|
Contents
|
Description: | Manufacturer | Acris Antibodies GmbH | | Quantity | 0.1 mg | | Reactivity | Human | | Presentation | Aff - Purified | | Applications | Enzyme Immunoassay, Western blot / Immunoblot | | Isotype | Ig | | Host | Rabbit | | PDF datasheet | view | | Shipping to | Worldwide | | Synonyms | c-ABL, p150, JTK7 | | Swiss Prot Num | P00519 | | Immunogen | This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human ABL1. | | Product Type | Antibodies | | Storage | Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Shelf life: one year from despatch. | | References | 1. Donaldson, L.W., et al., Proc. Natl. Acad. Sci. U.S.A. 99(22):14053-14058 (2002). 2. Pisabarro, M.T., et al., J. Mol. Biol. 281(3):513-521 (1998). 3. Nam, H.J., et al., Structure 4(9):1105-1114 (1996). 4. Chissoe, S.L., et al., Genomics 27(1):67-82 (1995). 5. Gosser, Y.Q., et al., Structure 3(10):1075-1086 (1995). | |
| Format | State: Liquid purified Ig | | ? | Purification: Protein A affinity chromatography. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with peptides. The antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS | | ? | Buffer System: PBS with 0.09% (W/V) sodium azide | |
| Specificity | This antibody reacts to ABL1. | | Application | ELISA: 1/1,000. Western blotting: 1/50 - 1/100. | | Background | The ABL1 protooncogene encodes a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. The t(9;22) translocation results in the head-to-tail fusion of the BCR and ABL1 genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for ABL1. | | Caution | This product is for research use only. Not for use in diagnostic or therapeutic procedures. | | Concentration | 0.25 mg/ml | |
|
|
|
|
